Having trouble accessing articles? Reset your cache.

Sutent misses OS endpoint in NSCLC study

Pfizer Inc. (NYSE:PFE) said top-line data showed Sutent sunitinib plus Tarceva erlotinib missed the primary

Read the full 153 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE